Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — Shareholder Meeting (November 2023)
26 slides from Racura Oncology's shareholder meeting presentation, Nov 27, 2023
Slide 1: ASX Announcement: Race Oncology 2023 Chair's Address & AGM Presentation
ASX Announcement Race Oncology 2023 Chair’s Address & AGM Presentation 27 November 2023 – Race Oncology Limited (“Race”) is pleased to attach a copy of the Chair’s address and CEO’s presentation for today’s Annual General Meeting (AGM) of shareholders. Mary Harney will provide the Chair’s address an
Slide 2: Announcement contacts and authorisation
Learn more at www.raceoncology.com. If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com. Race encourages all investors to go paperless by registering their d
Slide 3: Chair's Address - Race Oncology 2023 AGM
27 November 2023 Chair’s Address - Race Oncology 2023 AGM Good afternoon and welcome to Race Oncology’s Annual General Meeting for the 2023 financial year. My name is Mary Harney, and I am the Chair of the Board. Joining me on stage from the Race Board today are: Executive Director, Dr Pete Smith an
Slide 4: Chair's Address (continued)
I would also like to recognise the significant contribution of Phil Lynch. We owe a great vote of thanks to Phil for his strategic stewardship of Race over the past three years. He joined us initially as a Non- Executive Director, and then stepped up into the CEO role at a time when the company need
Slide 5: Chair's Address (continued)
The Phase 1 “all comers” or “basket” trial design enables us to include any pa�ents with relevant solid tumours. Given our prior history and experience with bisantrene, we s�ll expect it will have a strong relevance in breast cancer treatment and are strongly driven by the poten�al to help breast ca
Slide 6: At the Heart of Cancer Care - 2023 CEO AGM Presentation
N O V E M B E R 2 0 2 3 For personal use only AT THE HEART OF CANCER CARE 2 0 2 3 C E O A G M P R E S E N T A T I O N 0 1 ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
Slide 7: Important Notice and Disclaimer
Important Notice and Disclaimer A T T H E The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company). H E A R T THIS IS NOT A PROSPECTUS For personal use only This presentation is not a prospectus, product disclosure statement or disclosure document for
Slide 8: Why Invest in Race Oncology?
Why Invest in Race Oncology? A T T H E H E A R T Solid Clinical Strategy: cost effective Australian-focused clinical program across solid tumours For personal use only and AML designed to optimally leverage commercial opportunities in anticancer + O F cardioprotection, m6A RNA & AML C A N C E R C A
Slide 9: Bisantrene
Bisantrene A T T H E Small molecule chemotherapeutic with clinical efficacy in a diverse range of solid and H E A R T For personal use only hematological cancers O F C A N C E R Studied in over 50 clinical trials, 166 peer-reviewed publications. Approved for use in AML in France in 1988 C A R E Used
Slide 10: Bisantrene + Anthracycline: Improved Anticancer Activity
Bisantrene + Anthracycline A T Improved Anticancer Activity1 T H E H E A R T Bisantrene shows potent cell-killing activity against For personal use only Bisantrene significantly improves the cancer O F a diverse range of human cancers cell killing activity of doxorubicin C A N C E R 10000 Bisantrene
Slide 11: Bisantrene + Anthracycline: Protecting the Heart
Bisantrene + Anthracycline Protecting the Heart1 A T T H E H E A R T For personal use only O F C A N C E R Bisantrene protects the hearts of mice from permanent damage caused by the anthracycline doxorubicin Vehicle Heart protection was achieved using higher levels of C A R E Bisantrene chemotherapy
Slide 12: RC220 – a high value reformulation
New Bisantrene Formulation - RC2201 A T T H E H E A R T RC220 – a high value reformulation For personal use only O F • Proprietary formulation for peripheral and central line IV use C A N C E R • Designed to avoid drug precipitation issues whilst maintaining the activity and PK/PD properties of prio
Slide 13: Anthracyclines – Effective & Enduring
Anthracyclines* – Effective & Enduring A T T H E For personal use only H E A R T For most cancer patients, a therapy targetable Highly effective chemotherapeutics across a wide mutation cannot be identified, & immunotherapy is O F range of cancers ineffective C A N C E R C A R E Can cause serious ad
Slide 14: Anthracycline Cardiotoxicity
Anthracycline Cardiotoxicity A T T H E H E A R T For personal use only An under-appreciated problem in oncology O F Anthracyclines cause permanent damage to the hearts of patients C A N C E R Current solution – exclude use in high-risk patients and reduce lifetime dosing so that the acute, clinicall
Slide 15: Key Opinion Leaders
Key Opinion Leaders A T T H E H E A R T For personal use only It depends how carefully Toxicity is highest in the Scope for new cardio- 9-14% of patients on you look, but at least first year, but risk of O F protective therapy in anthracycline regimens 30% of patients who are heart failure remains a
Slide 16: RC220 Phase 1a/b Trial – Fully Funded
RC220 Phase 1a/b Trial – Fully Funded1 A T T H E H E A R T An ‘all comers’ Bayesian dose escalation Phase 1a trial of RC220 in any solid tumour patient where anthracycline use is indicated For personal use only O F Size: 25-50 patients; up to 10 sites in Australia and internationally C A N C E R Spo
Slide 17: RC220 Phase 1a/b Trial Outcomes
RC220 Phase 1a/b Trial Outcomes A T T H E H E A R T For personal use only Leverages an Australian-focused Phase 1a/1b trial design to ensure trial can be fully funded O F C A N C E R from existing cash resources C A R E Phase 1a establishes optimal bisantrene anthracycline dosing and safety Phase 1b
Slide 18: Cardioprotection & m6A RNA Phase Trial
Cardioprotection & m6A RNA Phase 2 Trial1 A T T H E H E A R T For personal use only A placebo-controlled, double-blinded, umbrella Bayesian combination trial of RC220. Focus on breast cancer plus any cancer or patient population that shows exceptional response to treatment in Phase 1 O F C A N C E R
Slide 19: AML Phase 1/2 Investigator Initiated Trial
AML Phase 1/2 Investigator Initiated Trial1 A T T H E H E A R T A low intensity salvage treatment for patients unable or unwilling to tolerate high intensity chemotherapy who have failed standard For personal use only of care AML treatments. O F C A N C E R Size: 40-60 patients; up to 10 sites in Au
Slide 20: Preclinical Activities
Preclinical Activities A T T H E H E A R T For personal use only O F C A N C E R C A R E Continue studies to determine the Develop the next generation Continue building the preclinical data Generate data to enable an cardioprotection mechanism of action bisantrene with a focus on the package needed
Slide 21: Bonus Option Timetable
Bonus Option Timetable A T T H E H E A R T Date Item For personal use only O F Announce Bonus Option Plan Wednesday, 22 November 2023 Lodge Appendix 3B and issue Cleansing Notice C A N C E R Ex Date of the Bonus Options Offer Wednesday, 29 November 2023 C A R E Record Date for Bonus Options Offer 7:
Slide 22: Coming Milestones
Coming Milestones A T T H E H E A R T For personal use only Bisantrene Phase 2 AML Trial Data to Filing Investigational New Drug O F be presented at the 65th ASH1 Annual application with US Food and Drug C A N C E R Meeting 9-12 Dec 2023 Administration for RC220 cGMP RC220 released by Ardena for Fir
Slide 23: Race – An Exciting Future
Race – An Exciting Future Bisantrene Market Potential – World1 A T T H E Uniquely situated to provide a future where the hearts of cancer patients are H E A R T For personal use only protected from the most widely used class of chemotherapeutics, anthracyclines O F C A N C E R Strong clinician suppo
Slide 24: Summary
Summary A T T H E H E A R T For personal use only Phase 1a/1b Australian trial fully funded from existing cash O F C A N C E R A clear and fully funded plan (subject to shareholder support) to generate C A R E Phase 2 efficacy data for the AML, solid tumour cardioprotection + anticancer & m6A RNA co
Slide 25: Questions
For personal use only Questions Race Oncology A T T H E H E A R T O F C A N C E R C A R E 20
Slide 26: Contact
For personal use only Contact DANIEL TILLETT Chief Executive Officer JANE LOWE Investor & Media Relations +61 2 8051 3043 +61 411 117 774 daniel.tillett@raceoncology.com jane.lowe@irdepartment.com.au ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749